Cooper Companies
COO Β· Health Care Supplies
$61.21
0.7%Dentsply Sirona
XRAY Β· Health Care Supplies
$9.43
0.7%The short version
- Cooper Companies is the larger business, with $4.1B of revenue in fiscal 2025 against $3.7B for Dentsply Sirona.
- Cooper Companies grew revenue faster (5.1%, against β3.0%).
- Cooper Companies kept more of each dollar of sales as operating profit (16.7% operating margin, against β11.5% operating margin).
- Cooper Companies turned more of its sales into free cash flow (10.6% FCF margin, against 2.8% FCF margin).
- Cooper Companies earned a higher return on the capital invested in it (4.3%, against β9.9%).
| Latest fiscal year | COO Β· FY25 | XRAY Β· FY25 |
|---|---|---|
| Size | ||
| Market cap | $11.8B | $1.9B |
| Revenue | $4.1B | $3.7B |
| Free cash flow | $434M | $104M |
| Net income | $375M | β$598M |
| Growth | ||
| Revenue growth | 5.1% | β3.0% |
| 5-year growth | 11.0% | 2.0% |
| Share count change | β0.2% | β1.9% |
| Profitability | ||
| Gross margin | 65.5% | 50.0% |
| Operating margin | 16.7% | β11.5% |
| Net margin | 9.2% | β16.3% |
| FCF margin | 10.6% | 2.8% |
| Return on capital | 4.3% | β9.9% |
| Return on equity | 4.6% | β36.5% |
| Balance sheet | ||
| Net debt | $2.4B | $2.0B |
| Net debt / EBITDA | 2.3x | β |
| Dividends and buybacks | $290M | $128M |
| Valuation & quality | ||
| P/E | 21.0x | β |
| Piotroski F-score | 5 | 6 |
FY16
COO $2.0B
XRAY $0.0M
FY17
COO $2.1B
XRAY $4.0B
FY18
COO $2.5B
XRAY $4.0B
FY19
COO $2.7B
XRAY $4.0B
FY20
COO $2.4B
XRAY $3.3B
FY21
COO $2.9B
XRAY $4.2B
FY22
COO $3.3B
XRAY $3.9B
FY23
COO $3.6B
XRAY $4.0B
FY24
COO $3.9B
XRAY $3.8B
FY25
COO $4.1B
XRAY $3.7B
COO
XRAY
FY16
COO 16.5%
XRAY β
FY17
COO 20.1%
XRAY β39.1%
FY18
COO 15.9%
XRAY β24.0%
FY19
COO 20.6%
XRAY 8.8%
FY20
COO 12.8%
XRAY β0.1%
FY21
COO 17.3%
XRAY 14.4%
FY22
COO 15.3%
XRAY β23.9%
FY23
COO 14.8%
XRAY β2.1%
FY24
COO 18.1%
XRAY β23.2%
FY25
COO 16.7%
XRAY β11.5%
COO
XRAY
FY16
COO $357M
XRAY $438M
FY17
COO $466M
XRAY $458M
FY18
COO $475M
XRAY $317M
FY19
COO $421M
XRAY $516M
FY20
COO $176M
XRAY $562M
FY21
COO $524M
XRAY $515M
FY22
COO $450M
XRAY $368M
FY23
COO $215M
XRAY $228M
FY24
COO $288M
XRAY $281M
FY25
COO $434M
XRAY $104M
COO
XRAY
FY16
COO 7.4%
XRAY 7.1%
FY17
COO 9.7%
XRAY β14.4%
FY18
COO 4.2%
XRAY β10.6%
FY19
COO 10.6%
XRAY 4.3%
FY20
COO 5.6%
XRAY β0.0%
FY21
COO 7.6%
XRAY 6.9%
FY22
COO 4.6%
XRAY β12.4%
FY23
COO 3.8%
XRAY β1.3%
FY24
COO 4.6%
XRAY β16.8%
FY25
COO 4.3%
XRAY β9.9%
COO
XRAY
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.